Latest News

Latest news is provided by our trusted partners at MJH Life Sciences® and its brands, and is not a publication of COS.

KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC

June 9, 2026

Caroline Seymour

Lack of a statistically significant PFS improvement and improbability of achieving OS benefit led to the discontinuation of the KEYNOTE-D46/EVOKE-03 trial in PD-L1–high NSCLC.

May’s GI Monthly Rewind: A Landmark Approval in CCA, Expanded Access for Daraxonrasib, and More Key Pipeline Updates

June 9, 2026

Courtney Flaherty

Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.

GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026

June 9, 2026

Kyle Doherty

ASCO 2026 genitourinary experts unpack key prostate and bladder cancer data, revealing practice-changing takeaways and what they mean for patient care.

Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma

June 8, 2026

Ashling Wahner

The EU has approved the use of subcutaneous isatuximab delivered via OBI across all existing indications for IV isatuximab for multiple myeloma.

Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer

June 8, 2026

Courtney Flaherty

Phase 1/2 data show that the PRMT5 inhibitor vopimetostat plus daraxonrasib yielded a 92% ORR in MTAP-deleted, RAS-mutant metastatic pancreatic cancer.

As 70% of Americans Live Beyond Cancer, City of Hope Sets the Standard for Lifelong Survivorship Care

June 8, 2026

City of Hope

City of Hope’s data-driven model integrates survivorship care from diagnosis through decades of follow-up.

INDEPENDENCE, Type II JAK Inhibitor Data Highlight Key MPN and AML Data Arriving at EHA 2026

June 8, 2026

Chris Ryan

Experts share the key myeloproliferative neoplasm and acute myeloid leukemia presentations they’re anticipating at the 2026 EHA Congress.

Romiplostim Significantly Reduces Chemo Dose Delays, Modifications Due to Thrombocytopenia in GI Cancers

June 8, 2026

Courtney Flaherty

In the phase 3 RECITE trial, romiplostim significantly reduced chemotherapy dose modifications due to thrombocytopenia vs placebo in gastrointestinal cancers.

Hematologists Highlight Top Data From ASCO 2026

June 8, 2026

Chris Ryan

Experts highlight some of the top hematologic oncology data presented at ASCO 2026, including key studies in multiple myeloma and diffuse large B-cell lymphoma.

Aglatimagene Besadenovec Plus EBRT Improves Prostate Cancer-Specific DFS

June 7, 2026

Kyle Doherty

Aglatimagene besadenovec plus ERBT displayed an accumulating benefit in high-risk prostate cancer after extended follow-up.

Five Under 5: Top Oncology Videos for the Week of 6/1/2026

June 7, 2026

OncLive Staff

The top 5 OncLive TV videos of the week cover insights in breast cancer, ovarian cancer, prostate cancer, acute myeloid leukemia, and mantle cell lymphoma.

The OncFive: Top Oncology Articles for the Week of 5/31

June 6, 2026

OncLive Staff

Check out some of the top oncology news and trends of the week.

Extended Pelvic Lymph Node Dissection Improves MFS in High-Grade Prostate Cancer

June 6, 2026

Kyle Doherty

Long-term follow-up data showed ePLND significantly reduces the risk of metastasis in ISUP GG 3-5 prostate cancer with radical prostatectomy.

From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving

June 5, 2026

Caroline Seymour

D. Ross Camidge, MD, PhD, reflects on his journey from a gap year at McDonald’s to directing the lung cancer program where he is now a patient.

Massachusetts Public Health Alliance’s 2026 Lemuel Shattuck Award presented to Dana-Farber’s Magnolia Contreras

June 5, 2026

Dana-Farber Cancer Institute

Magnolia Contreras, MSW, MBA, of Dana-Farber Cancer Institute, was honored with The Lemuel Shattuck Award for Significant Contributions to Public Health Practice.